CAS 361440-67-7 Munditia >98.5% (HPLC) Factory

Description:

(1S,3S,5S)-3-(Aminocarbonyl)-2-Azabicyclo [3.1.0]hexane-2-Carboxylic Acid tert-Butyl Ester

CAS: 361440-67-7

Puritas: >98.5% (HPLC)

Aspectus: pulveris albi

Medium API (CAS: 361442-04-8)

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ruifu Chemical Supple Related Intermedia
CAS 361442-04-8
CAS 945667-22-1
(R) -1-Boc-3-Aminopiperidine CAS 188111-79-7
(R)-(-)-3-Aminopiperidine dihydrochloride CAS 334618-23-4
Boc-3-Hydroxy-1-Adamantyl-D-Glycine CAS 361442-00-4
(1S,3S,5S)-3-(Aminocarbonyl)-2-Azabicyclo [3.1.0]hexane-2-Carboxylic Acid tert-Butyl Ester CAS 361440-67-7
2-(3-Hydroxy-1-Adamantyl)-2-Acidum Oxoaceticum, CAS 709031-28-7

Chemical Properties:

Nomen chemicum	(1S,3S,5S)-3-(Aminocarbonyl)-2-Azabicyclo[3.1.0]hexane-2-Carboxylic Acidum tert-Butyl Ester
Synonyma	N-Boc-L-cis-4,5-Methanoprolineamide;N-Boc-cis-4,5-Methano-L-Prolinamide;tert-Butyl (1S,3S,5S)-3-Carbamoyl-2-Azabicyclo[3.1.0]hexane-2-Carboxylate.
CAS Number	361440-67-7
CATTUS Number	RF-PI1990
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C11H18N2O3
M. Pondus	226.27
Ferveret	388.9±21.0℃
Density	1.228
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba pulveris
Puritas / Analysis Methodus	>98.5% (HPLC)
Damnum in Siccatio	<0.50%
Residere in Ignition	<0.20%
Individual Impurities	<1.00%
Totalis immunditias	<1.50%
Test Standard	Enterprise Standard
Consuetudinem	Medium API (CAS: 361442-04-8)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

(1S,3S,5S)-3-(Aminocarbonyl)-2-Azabicyclo[3.1.0]hexane-2-Carboxylicum acidum tert-Butyl Ester (CAS: 361440-67-7) intermedium est API (CAS: 361442 -04-8).(CAS: 361442-04-8) est oralis hypoglycemica (medicamentum anti-diabeticum) de dipeptidylo peptidase-4 (DPP-4) inhibitoris medicamentorum genus.Primae progressionis solum erat apud Bristol-Myers Squibb;anno 2007 AstraZeneca cum Bristol-Myers Squibb coniunxit ut coaevum supremum compositum et collaboraret in mercatu medicamento.Mense Iunio 2008, nuntiatum est Onglyza nomen commercii futurum sub quo venales essent.API (CAS: 361442-04-8) pro monotherapia adhibetur vel coniuncte cum aliis medicamentis ad diabetes generis curandos.Celeriter post administrationem oralis absorbetur et profile pharmacokineticae compatitur cum semel dosing cotidie.Ludit in inhibitione GLP-l degradationis.GLP-I Est hormona quae naturaliter intestino cibo sumta nascitur.